Dyne-101

Pfizer is prioritizing its oral obesity drug, danuglipron, with late-stage studies planned for the second half of 2025, aiming for a novel mechanism of action.

Dyne Therapeutics' DYNE-101 has been granted Fast Track Designation by the FDA, potentially accelerating its development for myotonic dystrophy type 1 (DM1).

Pfizer's Phase 3 CREST trial showed that sasanlimab combined with BCG significantly improved event-free survival in BCG-naive, high-risk NMIBC patients.

Dyne Therapeutics' DYNE-101 demonstrates compelling results in Phase 1/2 ACHIEVE trial for myotonic dystrophy type 1 (DM1).

The myotonic dystrophy therapeutic landscape is experiencing a surge in R&D, with over 20 companies actively involved in developing 22+ novel therapies.